Bosentan and the endothelin system in congestive heart failure
- PMID: 11097125
- PMCID: PMC6655168
- DOI: 10.1002/clc.4960231128
Bosentan and the endothelin system in congestive heart failure
Abstract
The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.
References
-
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415 - PubMed
-
- McMillen MA, Sumpio BE: Endothelins: Polyfunctional cytokines. J Am Coll Surg 1995; 180: 621–637 - PubMed
-
- Rubanyi GM, Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994; 46: 328–415 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical